Sarepta Therapeutics, Inc. 10-Q

Item 5. Other Information . During the three months ended June 30, 2026 , no director or officer (as defined in Rule 16a-1(f) under the Exchange Act) of the Company adopted or terminated contracts, instructions or written plans for the purchase or sale of our securities that are intended to satisfy the conditions specified in Rule 10b5-1(c) under the Exchange Act for an affirmative defense against liability for trading in securities on the basis of material nonpublic information. Item 6. Exhibits. The exhibits listed on the Exhibit Index immediately preceding such exhibits, which is incorporated herein by reference, are filed or furnished as part of this Quarterly Report on Form 10-Q. 87 EXHIBIT INDEX Incorporated by Reference to Filings Indicated Exhibit Number Exhibit Description Form File No. Exhibit Filing Date Provided Herewith 3.1 Amended and Restated Certificate of Incorporation. 8-K12B 001-14895 3.1 6/6/13 3.2 Amendment to the Amended and Restated Certificate of Incorporation . 8-K 001-14895 3.1 6/30/15 3.3 Certificate of Amendment to the Amended and Restated Certificate of Incorporation of Sarepta Therapeutics, Inc. 8-K 001-14895 3.1 6/8/20 3.4 Amended and Restated Bylaws . 8-K 001-14895 3.1 9/25/14 3.5 Amendment No. 1 to the Amended and Restated Bylaws. 8-K 001-14895 3.1 1/13/20 3.6 Second Amended and Restated Bylaws . 8-K 001-14895 3.1 12/13/22 3.7 Amendment No. 1 to Second Amended and Restated Bylaws of Sarepta Therapeutics, Inc. 8-K 001-14895 3.1 9/16/24 10.1† Sarepta Therapeutics, Inc. 2026 Equity Incentive Plan 8-K 001-14895 10.1 6/4/26 10.2† Sarepta Therapeutics, Inc. 2026 Employee Stock Purchase Plan 8-K 001-14895 10.2 6/4/26 10.3† Form of Stock Option Award Agreement under Sarepta Therapeutics, Inc. 2026 Equity Incentive Plan X 10.4† Form of Restricted Stock Unit Award Agreement under Sarepta Therapeutics, Inc. 2026 Equity Incentive Plan X 10.5† Employment Agreement, dated July 24, 2026, by and between Michael Severino, M.D., and Sarepta Therapeutics, Inc. 8-K 001-14895 10.1 7/27/26 10.6† Consulting and Advisory Agreement, dated July 26, 2026, by and between Douglas Ingram and Sarepta Therapeutics, Inc. 8-K 001-14895 10.2 7/27/26 10.7† Sarepta Therapeutics, Inc. 2024 Employment Commencement Incentive Plan S-8 POS 333-240996 4.5 3/28/24 10.8† Amendment No. 1 to the Sarepta Therapeutics, Inc. 2024 Employment Commencement Incentive Plan 8-K 001-14895 10.1 6/7/24 10.9† Amendment No. 2 to the Sarepta Therapeutics, Inc. 2024 Employment Commencement Incentive Plan S-8 333-297764 4.3 7/28/26 10.10† Amendment No. 3 to the Sarepta Therapeutics, inc. 2024 Employment Commencement Incentive Plan S-8 333-297764 4.4 7/28/26 31.1 Certification of the Company’s Principal Executive Officer, Michael Severino, M.D., pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. X 31.2 Certification of the Company’s Principal Financial and Accounting Officer, Ryan H. Wong, pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. X 32.1* Certification of the Company’s Principal Executive Officer, Michael Severino, M.D., pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. X 32.2* Certification of the Company’s Principal Financial and Accounting Officer, Ryan H. Wong, pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. X 101.INS Inline XBRL Instance Document - the instance document does not appear in the Interactive Data File as its XBRL tags are embedded within the Inline XBRL document X 101.SCH Inline XBRL Taxonomy Extension Schema With Embedded Linkbase Documents X 104 Cover page formatted as Inline XBRL and contained in Exhibit 101 X † Indicates management contract or compensatory plan, contract or arrangement. 88 * The Certifications attached as Exhibits 32.1 and 32.2 that accompany this Quarterly Report on Form 10-Q are not deemed filed with the SEC and are not to be incorporated by reference into any filings of Sarepta Therapeutics, Inc. under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, whether made before or after the date of this Form 10-Q, irrespective of any general incorporation language contained in such filing. 89 SIGNA TURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. SAREPTA THERAPEUTICS, INC. (Registrant) Date: August 5, 2026 By: /s/ MICHAEL SEVERINO, M.D. Michael Severino, M.D. Chief Executive Officer (Principal Executive Officer) Date: August 5, 2026 By: /s/ RYAN H. WONG Ryan H. Wong Executive Vice President, Chief Financial Officer (Principal Financial and Accounting Officer) 90